Jul, 2006

U.S.A.
News / Therapeutic Area News
OSI Pharmaceuticals Announces That Roche Has Received Negative CHMP Opinion in European Union on Tarceva(R) in Pancreatic Cancer
MELVILLE, N.Y.--(BUSINESS WIRE)--July 28, 2006--OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) announced today that Roche, its international partner for Tarceva® (erlotinib), received a negative...
Read More
U.S.A.
News / Therapeutic Area News
Study Demonstrates Improved Renal Function and Lipid Values in Kidney Transplant Patients on Prograf® Compared to Patients Taking Neoral®
BOSTON, July 25, 2006 – Research presented today at the World Transplant Congress (WTC) revealed that after only six months post-conversion from Neoral® (cyclosporine or CsA) to Prograf®...
Read More

Jun, 2006

U.S.A.
News / Therapeutic Area News
OSI Summarizes Clinical Data on Tarceva(R) at the 2006 American Society of Clinical Oncology (ASCO) Meeting
ATLANTA, Jun 06, 2006 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) today provided a summary of data from studies involving the company's leading product, Tarceva® (erlotinib),...
Read More
U.S.A.
News / Therapeutic Area News
Results From a Randomized Phase II Trial Suggested the Combinations of Avastin(R) Plus Tarceva(R) and Avastin Plus Chemotherapy Improved Progression- Free Survival in Advanced Non-Small Cell Lung Cancer
Genentech, Inc. (NYSE: DNA) and OSI Pharmaceuticals (Nasdaq: OSIP) today presented results from a Phase II study that compared the combinations of...
Read More

Apr, 2006

U.S.A.
News / Therapeutic Area News
Astellas Launches VAPRISOL® for the Treatment of Euvolemic Hyponatremia in Hospitalized Patients
Astellas Pharma US, Inc. today announced the launch and commercial availability of VAPRISOL® (conivaptan hydrochloride injection), an arginine vasopressin (AVP) receptor antagonist for the...
Read More